TY - JOUR T1 - Evaluation of a New Technique for iFOBT Utilising a New Sample Collection Device with Increased Buffer Stability JF - Anticancer Research JO - Anticancer Res SP - 3735 LP - 3740 VL - 37 IS - 7 AU - MARKUS BRUNS-TOEPLER AU - PHILIP HARDT Y1 - 2017/07/01 UR - http://ar.iiarjournals.org/content/37/7/3735.abstract N2 - Aims: The aims of the present study were: (i) Evaluate specificity and sensitivity of Hb Smart enzyme-linked immunosorbent assay (ELISA) (ScheBo Biotech) compared to colonoscopy results and (ii) assess stability of a new sample collection device containing a newly formulated buffer to extract haemoglobin using buffer and stool samples spiked with defined concentrations of haemoglobin. Materials and Methods: Stool samples were quantified with the ELISA method. The stability of haemoglobin in the extraction buffer and in native stool samples, respectively, was determined daily by ELISA during storage for 5 days at 4°C and at room temperature after addition of haemoglobin. Results: Haemoglobin ELISA had a sensitivity of 78.4% for detection of CRC with a specificity of 98%. Haemoglobin extracted in corresponding extraction buffer demonstrated stability throughout storage for 5 days at 4°C and at room temperature. Conclusion: Hb Smart represents a very promising tool for large-scale screening of CRC with regard to sample handling, stability and analysis of haemoglobin in faeces. ER -